Biotechnology - Research and Markets - RSS Feed

Yeast: Molecular and Cell Biology

press@researchandmarkets.com — Tue, 09 Feb 2010 16:39:21 GMT

Yeast is one of the oldest domesticated organisms and has both industrial and domestic applications In addition, it is very widely used as a eukaryotic model organism in biological research and has offered valuable knowledge of genetics and basic cellular processes In fact, studies in yeast have...

Click Chemistry for Biotechnology and Materials Science

press@researchandmarkets.com — Tue, 09 Feb 2010 16:24:49 GMT

Mimicking natural biochemical processes, click chemistry is a modular approach to organic synthesis, joining together small chemical units quickly, efficiently and predictably In contrast to complex traditional synthesis, click reactions offer high selectivity and yields, near-perfect reliability...

Biomedical Materials - Issue 1, 2010

press@researchandmarkets.com — Tue, 09 Feb 2010 15:34:36 GMT

A monthly news alert which addresses all the latest developments in ceramics, composites, metals, polymers and textiles for biomedical use including advances in materials, product launches and trials, industry news, international regulatory issues and an alerting service to the latest research...

Stem Cell Research - Market Trends, Investment Trends and Pipeline Analysis

press@researchandmarkets.com — Mon, 08 Feb 2010 12:22:17 GMT

“Stem Cell Research - Market Trends, Investment Trends and Pipeline Analysis” It is an essential source of information and analysis on global stem cell research and development This pharmaceutical and healthcare report identifies the key trends shaping and driving stem cell research and development...

Biomarkers, Tests and Trends for Drug R&D

press@researchandmarkets.com — Mon, 08 Feb 2010 09:45:14 GMT

This report is about the world market for biomarkers and tests used for drug R&D The study reviews and analyzes the market by examining biomarker related drug R&D spending, trends, major diseases, applications, M&As, alliances, tools & technologies, products and R&D services This report provides a...

Biofouling

press@researchandmarkets.com — Fri, 05 Feb 2010 11:34:29 GMT

Biofouling (the colonisation of an interface by a diverse array of organisms) is almost always a problem where it occurs, as it negatively affects surfaces, the materials that they are made from and the structures that they form, and can even destroy them This comprehensive book covers in detail in...

A Companion to Bioethics, 2nd Edition

press@researchandmarkets.com — Wed, 03 Feb 2010 17:14:19 GMT

This second edition of A Companion to Bioethics, fully revised and updated to reflect the current issues and developments in the field, covers all the material that the reader needs to thoroughly grasp the ideas and debates involved in bioethics - Thematically organized around an unparalleled range...

Advances in Bioceramics and Porous Ceramics, Volume 30, Issue 6

press@researchandmarkets.com — Wed, 03 Feb 2010 09:06:47 GMT

Improve your understanding in the most valuable aspects of advances in bioceramics and porous ceramics This collection of logically organized and carefully selected articles contain the proceedings of the “Porous Ceramics: Novel Developments and Applications” and “Next Generation Bioceramics”...

The Biotech Company League Table

press@researchandmarkets.com — Mon, 01 Feb 2010 12:33:41 GMT

The world’s first biotechnology company, Genentech, was founded in 1976. 30 years later there were 4,275 biotechnology companies worldwide, of which 710 were publicly listed. This Scrip analysis reviews the fortunes of the top 100 biotech companies involved in human healthcare on the basis of product sales and R&D investment.

Key topics covered:

- Biotech's winners of 2007
- Biotech's losers of 2007
- R&D expenditure
- The top 10 biotech products
- A snapshot of the top 10 companies

Products: Rituxan/MabThera, Neupogen/Neulasta, Herceptin, Aranesp, Avastin, Remicade, Enbrel, Humira, Lantus, Taxotere

Epigenetics and Human Health: Linking Hereditary, Environmental and Nutritional Aspects

press@researchandmarkets.com — Fri, 29 Jan 2010 14:01:44 GMT

The consequences of hereditary factors on human health and their interaction with environmental, nutritional and life style factors are topics which are at the center of public, governmental and scientific interest This handbook and ready reference work features an holistic introduction by Paolo...

Elements of Computational Systems Biology

press@researchandmarkets.com — Fri, 29 Jan 2010 12:24:04 GMT

Groundbreaking, long-ranging research in this emergent field that enables solutions to complex biological problems Computational systems biology is an emerging discipline that is evolving quickly due to recent advances in biology such as genome sequencing, high-throughput technologies, and the...

Stakeholder Opinions: Gene Therapy - Gene Therapy to Deliver after 20 Years of Clinical Development

press@researchandmarkets.com — Fri, 29 Jan 2010 09:02:43 GMT

Gene therapy looks to be coming of age, with seven projects in Phase III clinical development and one project currently under regulatory review. A shift in development from pure gene replacement to using gene therapy as a therapeutic delivery tool has enhanced the technology's commercial potential over the last 10 years.

Scope

- In-depth analysis of the current gene therapy clinical pipeline.

- Analysis of key target indications for gene therapies and key companies active in the filed.

- Key opinion leader review of technologies driving clinical gene therapy.

- Identification of drivers and inhibitors to the commercial success of gene therapy.

Highlights of this title

Most of the indications being targeted in the current gene therapy pipeline are multifactorial rather than monogenic in etiology. Reflecting this trend, cancer has become the leading therapy area for gene therapy development, constituting nearly half of the clinical projects under development.

The development of highly engineered recombinant viruses has increased the safety of gene therapy. As clinical evidence for the enhanced safety of these vectors gathers over the next few years, the perceived risk/reward profile for gene therapy will change in some disease areas.

With endless lucrative targets for companies developing safe and efficient delivery of genes, the commercial potential of gene therapy remains high.

Key reasons to purchase this title

- Quantify the gene therapy pipeline.

- Assess the changing vectors and target indications for gene therapy.

- Identify the leading companies involved in gene therapy development.

Top 10 Biotechnology Companies - SWOT Analysis, Competitive Benchmarking, Financial Analysis and R&D Pipeline

press@researchandmarkets.com — Thu, 28 Jan 2010 11:37:57 GMT

“Top 10 Biotechnology Companies - SWOT Analysis, Competitive Benchmarking, Financial Analysis and R&D Pipeline”, which provides an insight into the global biotechnology industry and analyzes the competitive positioning of the top 10 companies in the industry This pharmaceutical and healthcare report...

Advanced Biomaterials: Fundamentals, Processing, and Applications

press@researchandmarkets.com — Thu, 28 Jan 2010 09:34:58 GMT

Enables readers to take full advantage of the latest advances in biomaterials and their applications Advanced Biomaterials: Fundamentals, Processing, and Applications reviews the latest biomaterials discoveries, enabling readers to take full advantage of the most recent findings in order to advance...

U.S. Epigenetics Markets

press@researchandmarkets.com — Fri, 22 Jan 2010 12:15:06 GMT

Epigenetics is the study of heritable changes in gene expression that do not involve changes to the DNA sequence This additional level of transcriptional regulation goes beyond genetic information stored in the DNA sequence to regulate gene activity Thus, epigenetics is essentially the missing link...

Single Cell Analysis 2010: the New Frontier for 'Omics Market Report

press@researchandmarkets.com — Tue, 19 Jan 2010 11:06:16 GMT

’Omics has unleashed a deluge of data that underscores the complexity of biological systems Simplification and specificity is the new dogma, and one of the most promising approaches is single cell analysis No longer are large groups of cells containing high and low responders, early and late...

Biotech 2009 CRO Quality Benchmarking Report

press@researchandmarkets.com — Wed, 13 Jan 2010 12:49:57 GMT

This is a substantial study based on interviews with 44 biotechnology company representatives, rating 130 unique projects with CROs Respondents graded 10 prominent service providers across 18 important capabilities that affect provider selection and delivery quality The report contains 139 pages,...

Asia Pacific Market for Bone Graft Substitutes and Other Biomaterials 2009

press@researchandmarkets.com — Fri, 08 Jan 2010 15:05:43 GMT

The Asia-Pacific market includes Japan, South Korea, and Australia In 2008, the combined Asia-Pacific market for dental bone graft substitutes (BGS) and other biomaterials was valued at nearly US$62 5 million The economic recession, beginning in 2008, led to a decline in the unit growth ate of the...

Biomedical Materials - Issue 12, 2009

press@researchandmarkets.com — Wed, 06 Jan 2010 16:20:38 GMT

Stem Cells for Cellular Therapy 2010 Market Report

press@researchandmarkets.com — Wed, 06 Jan 2010 11:13:59 GMT

This is the latest and most up-to-date Market Report from Select Biosciences addressing the cellular therapy space Select Biosciences’ industry coverage of the stem cells space is broad and comprehensive—each segment of the space is therefore analyzed and presented in detail in a market report This...

The Future of Biosimilars - Market Forecasts to 2015, Opportunity Analysis and Regulatory Pathways

press@researchandmarkets.com — Tue, 05 Jan 2010 17:15:40 GMT

“The Future of Biosimilars - Market Forecasts to 2015, Opportunity Analysis and Regulatory Pathways” provides insights on the biosimilars market revenues and growth until 2015 Further, the distribution of revenues across key geographies such as the US, the top five countries in Europe and Japan are...

Biopharma Quarter: Key Trends and Events of the Third Quarter of 2009

press@researchandmarkets.com — Wed, 23 Dec 2009 11:41:07 GMT

The rules of the game in healthcare are changing Although U S healthcare reform has yet to coalesce, the European Union is cracking down on generics shipments, stirring up controversy about trade rules and counterfeit drugs, and ratcheting up its oversight of antitrust laws, launching an...

Assessment of Innovations in Biochips

press@researchandmarkets.com — Mon, 21 Dec 2009 17:28:35 GMT

This research service discusses the assessment of innovations in biochips This Frost & Sullivan research service titled Assessment of Innovations in Biochips (Technical Insights) analyzes the economic scenarios for biochip applications and the key driving forces and challenges and provides a...

Biotech and Pharma Stock List

press@researchandmarkets.com — Thu, 03 Dec 2009 09:43:29 GMT

Investor Ideas Biotech and Pharma Directory lists publicly traded biotech and pharma companies on global stock exchanges with company descriptions, stock symbols and hyperlinks to company url and quotes Global Directory of Publicly Traded Biotech,Pharma and Life Sciences Stocks ,on the TSX, TSX...

Biodiesel Science and Technology: From Soil to Oil

press@researchandmarkets.com — Tue, 01 Dec 2009 09:58:19 GMT

Biodiesel production is a rapidly advancing field worldwide, with biodiesel fuel increasingly being used in compression ignition (diesel) engines Biodiesel has been extensively studied and utilised in developed countries, and it is increasingly being introduced in developing countries, especially in...

Emerging Biotech Sector in Malaysia

press@researchandmarkets.com — Mon, 30 Nov 2009 16:01:51 GMT

Malaysia has emerged as a major investment destination for biotech companies The Malaysian biotech market posted high growth last year and is expected to do the same in next few years Rich biodiversity, availability of low cost human resources and strong government efforts are some of the reasons...

Advances in the Stem Cell Industry: The Future Impact of Innovation, and an Evaluation of the Commercial Landscape

press@researchandmarkets.com — Tue, 24 Nov 2009 12:05:49 GMT

An important milestone in the development of stem cell technology occurred in 2007, when researchers induced human cells into a stem cell state using defined genetic factors These cells are now known as induced pluripotent stem (IPS) cells; they offer an alternative to using embryonic stem cells...

Competitor Analysis: CXCR and CXCL Agonists and Antagonists

press@researchandmarkets.com — Mon, 23 Nov 2009 11:53:09 GMT

The present Competitive Intelligence Report about CXCR agonists and CXCR/CXCL antagonists provides a competitor evaluation in the field of chemokine receptor CXCR or its ligands CXCL targeting molecules for tissue regeneration or treatment of cancer and inflammatory diseases of lung, skin or colon...

Competitor Analysis: Heat shock protein 90 (Hsp90) Inhibitors

press@researchandmarkets.com — Mon, 23 Nov 2009 11:38:23 GMT

The present Competitive Intelligence Report about Heat shock protein 90 (Hsp90) Inhibitors provides a competitor evaluation in the field of novel small molecules and antibodies targeting the heat shock protein 90 (Hspo90) chaperone for treatment of cancer as of November 2009 Purchase of the...

Beneluxian Market for Dental Bone Graft Substitutes and Other Biomaterials 2009

press@researchandmarkets.com — Thu, 19 Nov 2009 14:23:59 GMT

The Beneluxian market for dental bone graft substitutes and other biomaterials, which includes Belgium, the Netherlands and Luxemburg, was the seventh largest in Europe in 2008 The Netherlands represented the vast majority of this market, which grew significantly in 2007 The rapid growth in the...

Marine Biotechnology - Worldwide Market Trends

press@researchandmarkets.com — Tue, 17 Nov 2009 10:35:58 GMT

Comprising the largest part of the planet's biosphere, the marine environment contains the most diverse and ancient forms of life. The advent of advanced scientific disciplines such as molecular biology, genomics, bioinformatics and application of information technology to biotechnology, has tremendously enhanced human understanding of marine life. Widening applications in several end-use areas including marine transportation, environmental remediation, cosmetics, research, and food sectors also contributed to market growth. However, the industry is still in a nascent stage and is a significantly small part of the overall biotech market.

These and other market data and trends are presented in "Marine Biotechnology: Worldwide Market Trends" by BizAcumen, Inc. Our reports are designed to be most comprehensive in geographic coverage and vertical market analyses

Genetic Testing - A Global Update of Market Trends & Opportunities

press@researchandmarkets.com — Tue, 17 Nov 2009 10:35:56 GMT

Genetic testing, which of-late has been transforming itself from service driven to product-driven market is expected to provide an impetus to diagnostic companies with respect to expansion of their operations. Genetic testing market has been witnessing a rise in demand from various quarters, which include medical, paternity & forensics departments, immigration & insurance sectors and DNA banks. Increasing emphasis on the need to develop new and more effective testing methods is projected to further propel the market growth. The early detection of genetic disorders using genetic testing would significantly reduce morbidity as well mortality rates.

These and other market data and trends are presented in "Genetic Testing: A Global Update of Market Trends & Opportunities" by BizAcumen, Inc. Our reports are designed to be most comprehensive in geographic coverage and vertical market analyses.

Collagen and HA-based Biomaterials - Global Trends

press@researchandmarkets.com — Tue, 17 Nov 2009 10:35:55 GMT

Biomaterials are considered one of the most exciting areas for medical devices The future holds immense potential in terms of developing new products with wide application range Technological breakthroughs in fields such as "dermal implants" will lead to preference/choice of treatment in future...

Gene Therapy - Worldwide Market Challenges & Opportunities

press@researchandmarkets.com — Tue, 17 Nov 2009 10:35:54 GMT

Gene therapy promises to be one of the most important frontiers in medicine. Although no significant achievements for curing disease have been achieved, the future seems to hold significant potential in terms of developing such approaches. Advancements in gene therapy have provided useful data, which has helped in understanding the pathogenesis of diseases. The discipline heralds a significant potential for the biotechnology industry over the very long term, as the approach moves from research labs to clinical trials. Proteins and monoclonal antibodies have revolutionized the treatment of a wide variety of diseases, and gene-based therapies that deliver the DNA sequences encoding proteins and antibodies signify the next big step in the evolution of biopharmaceuticals. Gene therapy market is still in the experimental stages with success yet to be achieved in developing completely curative therapeutic drugs.

These and other market data and trends are presented in "Gene Therapy: Worldwide Market Challenges & Opportunities" by BizAcumen, Inc. Our reports are designed to be most comprehensive in geographic coverage and vertical market analyses.

Gene Amplification Technologies - Trends & Opportunities Worldwide

press@researchandmarkets.com — Tue, 17 Nov 2009 10:35:53 GMT

Molecular diagnostics and the Human Genome Project have been the major growth drivers for gene amplification technology. Amplification is a mechanism by which cells are amplified or synthesized from a single copy of gene. Gene amplification technology addresses applications in molecular biology research (DNA amplification), gene therapy, drug discovery, forensic identification, and diagnosis.

Gene amplification technology plays a vital role in the diagnostics field. With increasing aging population, countries worldwide face the challenge of preventing age-related diseases such as cardiovascular diseases and diabetes. This indicates the requirement of new diagnostics including genetic testing which make use of gene amplification technology. With growing improvements in the diagnostic market, the DNA diagnostic technologies are set to achieve superior efficiencies and improved activity in numerous application areas, including healthcare, biomedical research, toxicology, bioremediation, forensics and personnel identification, environmental monitoring, quality control in the food industry, and agriculture.

These and other market data and trends are presented in "Gene Amplification Technologies: Trends & Opportunities Worldwide" by BizAcumen, Inc. Our reports are designed to be most comprehensive in geographic coverage and vertical market analyses.

Biocompatible Materials - A Global Market Trajectory

press@researchandmarkets.com — Tue, 17 Nov 2009 10:35:52 GMT

Rapid development of tissue engineering as a prime technology in research sciences is largely anticipated to shape the future of biocompatible materials. Other factors to reckon with include advancements in fundamental understanding of biocompatibility science, expanding arena of coating technology, and the development of novel synthetic materials for medical applications. Nanotechnology is also used for creating very small, compact biomaterial devices including drug delivery vehicles and medical implants. Biocompatible materials are fast turning out to be a challenging area of research in the biosciences field. Several innovative products such as total artificial heart system, pneumatic total artificial heart, artificial blood vessels, and artificial blood among others are being developed that can be effectively used as substitutes for human body parts.

These and other market data and trends are presented in "Biocompatible Materials: A Global Market Trajectory" by BizAcumen, Inc. Our reports are designed to be most comprehensive in geographic coverage and vertical market analyses.

Automated and Rapid Microbiological Tests - A Worldwide Market Review

press@researchandmarkets.com — Tue, 17 Nov 2009 10:35:52 GMT

High prevalence of infectious diseases and sexually transmitted diseases (STDs) continue to drive the automated and rapid tests market, as need for quicker, higher volume and more accurate methods of testing gains importance. With humans and bacteria locked in a perennial biological warfare, there exists a perpetual need for new and advanced rapid microbial testing methods and instruments. Hitherto growth in the automated microbiological test systems market stemmed from laboratories worldwide embarking on the transition from manual to automated forms of testing.

Technology developments and changes have initiated sweeping changes in the market for automated and rapid microbiological tests. With probe tests threatening the survival of immunoassay based rapid tests and with advances in automated microbiological testing systems promising potential opportunities, the landscape is fraught with a unique mixture of opportunities and related threats. The new methods offer greater speed, accuracy, specificity and sensitivity than can be achieved with conventional culturing or immunoassay methods. Molecular diagnostics is the new enabling technology of numerous next generation rapid microbiology test kits.

These and other market data and trends are presented in “Automated and Rapid Microbiological Tests: A Worldwide Market Review” by BizAcumen, Inc. Our reports are designed to be most comprehensive in geographic coverage and vertical market analyses.

Agricultural Biotechnology - Global Market Trends

press@researchandmarkets.com — Tue, 17 Nov 2009 10:35:52 GMT

Biotechnology is considered to be the most promising technology that can provide lasting solution to various problems ranging from food shortage to preservation of environmental resources Much of the interest in biotechnology stems from rapid dissemination in North America and other exporting...

Probiotics - A Global Update of Market Trends & Opportunities

press@researchandmarkets.com — Tue, 17 Nov 2009 10:35:52 GMT

Probiotics are considered to be the vital healthcare concept of the 21st century. As people become increasingly health conscious, preventive medicine in the form of probiotic foods is gaining popularity. While already widely known and put to extensive use by Asians and Europeans, the trend for probiotics is catching up with the world populace. Probiotics is witnessing extensive scientific research work as new probiotic strains and new applications are under development. Apart from gastrointestinal problems, new target areas for probiotics include inflammatory diseases, allergy prevention, cholesterol reduction and prevention of colon cancer.

The issue of genetically modified cultures, however, threatens the market. To counter this problem, many marketers are promoting their products to be free from genetically modified organisms (GMOs). Some supplement companies in order to increase their market share are making health claims that are misleading and lack scientific evidence. This may influence the market negatively, as consumer confidence in probiotics products gets tampered and it requires high marketing efforts to get them back to the market.

These and other market data and trends are presented in “Probiotics: A Global Update of Market Trends & Opportunities” by BizAcumen, Inc. Our reports are designed to be most comprehensive in geographic coverage and vertical market analyses.

Biometrics - Trends & Opportunities Worldwide

press@researchandmarkets.com — Tue, 17 Nov 2009 10:35:51 GMT

Increasing security concerns ranging from individual identity theft, corporate security, to even national security represents factors that are important to the biometrics market. Some countries have already rolled out biometric systems at airports and other ports of entry to check flow of illegal immigrants into their respective territories. On the technological front, non-contact systems could emerge as the answer to expel inhibitions exhibited by users. Development of industry-wide standards has been initiated by some industry groups, which would lead to lower costs and enable easier adoption of present and emerging technologies. Government initiatives could emerge as the key to biometrics growth.

These and other market data and trends are presented in “Biometrics: Trends & Opportunities Worldwide” by BizAcumen, Inc. Our reports are designed to be most comprehensive in geographic coverage and vertical market analyses.

Biochips - A Global Update of Market Trends & Opportunities

press@researchandmarkets.com — Tue, 17 Nov 2009 10:35:51 GMT

Significant dimensions of the vast parallel studies afforded by biochips have created a holistic means of viewing biological systems In addition to the combination of various sciences, space, time and expense are all key factors in the future development of biochips Modern day chips can contain a...

Signal Crosstalk in Plant Stress Responses

press@researchandmarkets.com — Tue, 17 Nov 2009 10:20:05 GMT

Signal Crosstalk in Plant Stress Responses summarizes the current body of knowledge on crosstalk between plant stresses, providing a further understanding of the complexity of signal crosstalk Since plants are continually exposed to multiple stresses, the signal transduction pathways must...

Success Rates in Biotech - Going The Wrong Way

press@researchandmarkets.com — Mon, 16 Nov 2009 11:50:35 GMT

The report "Success Rates in Biotech - Going The Wrong Way" summarises our review of 211 public biotech companies comprising over 1,500 drug development projects We have studied the clinical pipelines going back to 2002 based on financial reports and found a striking difference of success...

Developing Managed Care Pull-Through Excellence

press@researchandmarkets.com — Mon, 16 Nov 2009 09:26:25 GMT

In today's pharmaceutical marketplace, companies not only have to fight to win product placement on Managed Care formularies but also to ""pull through"" the business and increase market share after a win To benefit from formulary wins, savvy companies ensure that their sales forces and account...

Managed Markets Account Management: Assessing the Performance of Account Executives

press@researchandmarkets.com — Mon, 16 Nov 2009 09:14:53 GMT

This study was conducted to identify common performance measurement practices across geographies and hierarchy, provide insight into effective evaluation of the function and determine measures that drive functional success Today's market driven environment has made performance assessment of managed...

Best Practices for Post-Marketing Surveillance of Adverse Events within the U.S.

press@researchandmarkets.com — Fri, 13 Nov 2009 16:00:09 GMT

Medical and scientific progress has been enormous in the past decades However, this has also raised several safety issues leading to increased vigilance on bio-pharma companies by the U S Food and Drug Administration Authority Under such circumstances, it is imperative for the bio-pharmaceutical...

Best Practices for Internal Communications Regarding Brands & Disease States

press@researchandmarkets.com — Fri, 13 Nov 2009 15:45:39 GMT

When a promising new pharmaceutical product fails to meet expectations, poor brand communications may be a contributing cause Successful brand leaders today must understand how and when to deliver complex key messages to all audiences -- including internal stakeholders -- to realize the best new...

2010 Plimsoll Analysis - Bioscience - A comprehensive profile of 186 companies operating in the UK market

press@researchandmarkets.com — Wed, 11 Nov 2009 15:34:45 GMT

The UK Bioscience market analysis This edition of the Plimsoll Analysis is the most comprehensive review yet of the UK Bioscience industry With the market due for a prolonged period of consolidation to weed out over capacity and weakened competitors, keeping up with development will be vitally...

Pharmaceutical Industry in South Africa

press@researchandmarkets.com — Tue, 03 Nov 2009 10:10:41 GMT

The birth origins of the Pharmaceutical Industry can be traced back to more humble antecedents than just chemistry labs The earliest incidents of recognition of the antiseptic properties of the dyestuffs is around the late 19th century The invention of penicillin can yet be recognized as a major...

Pharmaceutical Industry in Czech Republic

press@researchandmarkets.com — Tue, 03 Nov 2009 10:08:44 GMT

Pharmaceutical Industry in Russia

press@researchandmarkets.com — Tue, 03 Nov 2009 10:06:54 GMT

Pharmaceutical Industry in Germany

press@researchandmarkets.com — Tue, 03 Nov 2009 10:05:09 GMT

Pharmaceutical Industry in Belgium

press@researchandmarkets.com — Tue, 03 Nov 2009 10:03:22 GMT

Pharmaceutical Industry in Hungary

press@researchandmarkets.com — Tue, 03 Nov 2009 10:01:30 GMT

Pharmaceutical Industry in Taiwan

press@researchandmarkets.com — Tue, 03 Nov 2009 09:59:30 GMT

Pharmaceutical Industry in Norway

press@researchandmarkets.com — Tue, 03 Nov 2009 09:57:32 GMT

Pharmaceutical Industry in Brazil

press@researchandmarkets.com — Tue, 03 Nov 2009 09:55:21 GMT

Pharmaceutical Industry in the Netherlands

press@researchandmarkets.com — Tue, 03 Nov 2009 09:38:27 GMT

Pharmaceutical Industry in Italy

press@researchandmarkets.com — Tue, 03 Nov 2009 09:36:17 GMT

Pharmaceutical Industry in South Korea

press@researchandmarkets.com — Tue, 03 Nov 2009 09:34:03 GMT

Pharmaceutical Industry in Spain

press@researchandmarkets.com — Tue, 03 Nov 2009 09:29:32 GMT

Pharmaceutical Industry in Japan

press@researchandmarkets.com — Tue, 03 Nov 2009 09:27:29 GMT

Pharmaceutical Industry in Sweden

press@researchandmarkets.com — Tue, 03 Nov 2009 09:25:33 GMT

Pharmaceutical Industry in Denmark

press@researchandmarkets.com — Tue, 03 Nov 2009 09:23:22 GMT

Pharmaceutical Industry in Poland

press@researchandmarkets.com — Tue, 03 Nov 2009 09:21:21 GMT

Future of Green Biotechnology in China

press@researchandmarkets.com — Mon, 02 Nov 2009 11:12:50 GMT

This report is the unique and latest one available in the world to provide good understanding about Green Biotechnology (GB) in China and to find out business opportunities in this field The first edition of this report is finished soon in October 2009 Green biotechnology (GB) is mainly based on...

Genetic Engineering - Global Outlook

press@researchandmarkets.com — Mon, 02 Nov 2009 08:53:32 GMT

The global outlook series on Genetic Engineering provides a collection of market briefs and concise summaries of research findings. The report offers a bird’s eye view of the industry, highlights latest developments, and discusses demand drivers, issues and concerns, and regulatory environment. Discussion on the industry’s most noteworthy regional market, the US, is amply detailed with unbiased research commentary to provide the reader a rudimentary understanding of the prevailing market climate. The report also provides select data on regional markets. Also included is an indexed, easy-to-refer, fact-finder directory listing the addresses, and contact details of 169 companies active in the market.

Please note: Reports are sold as single-site single-user licenses. The delivery time for hard copies is between 3-5 business days, as each hard copy is custom printed for the organization ordering it. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks.

For information on site licence pricing please click on Enquire before buying

Cord Blood Stem Cells - A Global Market Overview

press@researchandmarkets.com — Thu, 29 Oct 2009 09:51:42 GMT

Umbilical cord and placenta, once considered medical waste are emerged to be a valuable source of stem cells The cord blood stem cells show the potential to treat the fatal diseases such as leukemia, cardiac attacks and debilitating diseases including Alzheimer’s and Parkinson’s Cord blood stem...

The Market Outlook for Research Products in FY2010

press@researchandmarkets.com — Thu, 29 Oct 2009 09:18:26 GMT

Money is starting to flow The 8 2 billion dollars appropriated to the NIH Scientific Research program by the American Recovery and Reinvestment Act is being earmarked for lab renovations, Challenge Grants, the Shared Instrumentation Program and research that spans multiple public and non-profit...

Global Top 10 Biotechnology Companies — Industry, Financial and SWOT Analysis

press@researchandmarkets.com — Tue, 27 Oct 2009 12:32:44 GMT

Scope:

‘Top 10 Global Biotechnology Companies Report: Strategic evaluation of industry and key players’ is a business report that provides a comprehensive view of the global biotechnology industry and its top 10 companies.

The report includes the following:

- Industry analysis including market value, market volume, market share and forecast growth till 2012
- Assessment of intensity of competition based on five-forces model including degree of rivalry, substitutes, new entrants, buyer power and supplier power
- SWOT and 5-year financial analysis of top 10 players in the industry
- Descriptive profiles of the leading players including the strategic initiatives undertaken by them in the last 12 months

The top 10 companies have been ascertained based on their global revenues for the financial year 2008.

Highlights:

The global biotechnology market generated total revenues of $171.8 billion in 2007, representing a compound annual growth rate (CAGR) of 10.7% for the period spanning 2003-07. The performance of the market is forecast to decelerate, with an anticipated CAGR of 9.9% for the five-year period 2007-12, which is expected to drive the market to a value of $275.8 billion by the end of 2012.

The top 10 global biotechnology companies recorded revenues of $56.7 billion during 2008, an increase of 12.6% over FY2007. The operating profit of these companies was $15.1 billion in FY2008, an increase of 12.1% over FY2007. The net profit was $10.5 billion during FY2008, an increase of 10.3% over FY2007.

The average operating margin of the top 10 companies was 17% in FY2008 as compared with that of 20.2% in FY2007. The net margin was 10.3% in 2008 as compared with that of 14.9% in 2007.

Since 2003, the global biotechnology market has witnessed a significant growth across different geographies. However, the market growth is expected to decelerate for next few years due to increased number of patent expiries and intensifying competition from biosimilars.

Reasons to

Pharma 101: An Overview of the Life Sciences Industry (Analyst Insight)

press@researchandmarkets.com — Tue, 27 Oct 2009 12:32:11 GMT

The life sciences industry is unique and complex. Without having the proper background, it can be difficult for IT vendors to enter this conservative market. Those willing to put in the extra effort to truly understand the pharmaceutical and biotechnology industries will realize there is considerable opportunity for technology.

Scope

- Offers an overview of the pharmaceutical and biotechnology industries

- Discusses key areas where technology would be most beneficial in the life sciences industry

- Provides go-to-market strategies to help penetrate the pharma and biotech markets

Highlights of this title

On average, it takes about 10-12 years and $1 billion to bring a new drug to market. With a patent life of only 20 years, this does not leave a long market exclusivity period in which to recoup the development costs. Therefore, executives are beginning to look at various technology solutions to lower costs and reduce time-to-market.

Companies are shifting away from the 'one-size-fits-all' blockbuster drug business model. As pressures grow to fill their dwindling product pipeline with innovative drugs, companies are embracing biotechnology and personalized medicine. This has led to a greater demand forthe IT sector to provide the industry with the tools it requires to succeed.

In the past, pharma companies have built their own solutions as they required customized solutions, resulting in an industry plagued with home-grown legacy systems that are difficult to maintain and integrate. IT executives are now beginning to understand the benefits of commercial solutions, but still need time, education and convincing.

Key reasons to purchase this title

- Understand the pharmaceutical and biotechnology product lifecycle

- Identify emerging areas of concern for pharmaceutical and biotechnology companies

- Gain insight into what solutions and services that will appeal most to life sciences companies

2009 CRO Quality Benchmarking Study - CRO Selection for Biotechnology Companies

press@researchandmarkets.com — Thu, 22 Oct 2009 13:51:53 GMT

Capitalizing on Opportunities in Cord Blood Industry Growth

press@researchandmarkets.com — Wed, 21 Oct 2009 14:12:21 GMT

Over the past 12 months, the cord blood banking industry has expanded through double digit growth, due to new entrants in the cord blood banking industry as well as revenue growth at existing operations Deeper analysis reveals that of existing cord blood banks, most fall into one of two “camps,”...

China: A New Era of Innovation in Drug Development

press@researchandmarkets.com — Mon, 19 Oct 2009 11:12:03 GMT

In the latest edition from our Clinical Trials Special Report Series, we break down China’s clinical trials landscape and analyze the government investments that are making the country more attractive for inclusion in global drug development programs of pharma companies of all sizes Key Features...

European Lab-on-chip and Microfluidics Markets

press@researchandmarkets.com — Thu, 08 Oct 2009 08:36:33 GMT

This research service gives a detailed analysis of the lab-on-chip and microfluidics market in Europe from 2005-2015...

2009 Chemicals, Pharmaceuticals, Medical Products & Biotechnology - UK Key Corporate Changes

press@researchandmarkets.com — Tue, 06 Oct 2009 08:12:51 GMT

The Mandis 2009 Key Corporate Changes report for the UK Chemicals, Pharmaceuticals, Medical Products & Biotechnology Sector will put you ahead of your competition in terms of market knowledge This is an in depth report detailing 304 key changes and developments, covering 196 different companies...

Clinical Bacteriology

press@researchandmarkets.com — Mon, 28 Sep 2009 13:19:03 GMT

In this concise, beautifully illustrated book, the authors introduce the reader to the basic science of medical bacteriology and relate this to clinical practice By integrating the text with over 270 full-colour diagrams and selected photomicrographs, the book explains the essentials of bacterial...

Fluorescence Applications in Biotechnology and Life Sciences

press@researchandmarkets.com — Mon, 28 Sep 2009 11:02:21 GMT

A self-contained treatment of the latest fluorescence applications in biotechnology and the life sciences This book focuses specifically on the present applications of fluorescence in molecular and cellular dynamics, biological/medical imaging, proteomics, genomics, and flow cytometry It raises...

Modern Biotechnology : Connecting Innovations in Microbiology and Biochemistry to Engineering Fundamentals

press@researchandmarkets.com — Thu, 24 Sep 2009 15:26:54 GMT

A unique resource for the next generation of biotech innovators Enabling everything from the deciphering of the human genome to environmentally friendly biofuels to lifesaving new pharmaceuticals, biotechnology has blossomed as an area of discovery and opportunity Modern Biotechnology provides a...

Biosimilars (2009 - 2014)

press@researchandmarkets.com — Thu, 24 Sep 2009 14:46:57 GMT

The impending expiry of several patented blockbuster biopharmaceuticals and the increasing demand from patients, insurers, and government agencies to reduce drug costs have created numerous opportunities in the global biosimilars market The global biosimilars market is expected to be worth US$19 4...

Russia Biofuels Market Potential

press@researchandmarkets.com — Mon, 21 Sep 2009 16:53:53 GMT

Biofuel is any fuel that is derived from biomass - recently living organisms or their metabolic byproducts, such as manure from cows It is a renewable energy source, unlike other natural resources such as petroleum, coal, and nuclear fuels Ethanol is manufactured from microbial conversion of biomass...

Who Cloned My Cat?: Fun Adventures in Biotechnology

press@researchandmarkets.com — Mon, 21 Sep 2009 11:17:12 GMT

"Science is fun!" Is the motto of this fun-filled book by Prof Reinhard Renneberg Do you know that in Japan, washing machines have no "cooking program" thanks to enzyme detergents? How to make German-style beer from rice? How do you make real snow with dead frost-bacteria? Is using bio-ethanol as a...

Nanotherapeutics: Drug Delivery Concepts in Nanoscience

press@researchandmarkets.com — Mon, 21 Sep 2009 10:51:17 GMT

An important and exciting aspect in the newly developing field of nanomedicine is the use of nanoparticle drug delivery systems allowing for innovative therapeutic approaches Due to their small size, these drug delivery systems are promising tools in therapeutic approaches such as selective or...

Carbon Nanotubes: Angels or Demons?

press@researchandmarkets.com — Fri, 18 Sep 2009 14:50:19 GMT

The field of C-nanoparticles toxicity is, at present, fragmented and contradictory, oscillating between enthusiastic raptures and bitter disappointments This important book presents an overall, unitary view of the carbon nanoparticle world, in which both the positive and negative aspects of these...

Dendrimer-Based Nanomedicine

press@researchandmarkets.com — Fri, 18 Sep 2009 14:37:22 GMT

In recent decades, dendrimers — free-shaped synthetic macromolecules — have garnered a great deal of scientific interest due to their unique molecular nanostructure Used in a variety of scientific applications, the use of dendrimers is now widely regarded as a safer, more precise, and more effective...

Nanobiotechnology And Nanobiosciences

press@researchandmarkets.com — Fri, 18 Sep 2009 13:54:58 GMT

Nanobiotechnology is capable of yielding a scientific and industrial revolution, as envisioned by the numerous programs on nanotechnology launched over the last decade by councils and governments worldwide, beginning in late 1995 by the Science and Technology Council in Italy, by President Clinton...

Nanopathology: The Health Impact of Nanoparticles

press@researchandmarkets.com — Fri, 18 Sep 2009 13:53:38 GMT

Enormous funds are currently being invested in nanotechnology, yet very little is known about how its products and by-products can interfere with organisms, both end-users and people involved in their manufacture Similar scenarios are already widely known in the history of science, such as the...

Competitor Analysis: EGF-R Agonists and Antagonists

press@researchandmarkets.com — Thu, 17 Sep 2009 13:31:03 GMT

The present Competitive Intelligence Report about EGF-R agonists and antagonists provides a competitor evaluation in the field of epidermal growth factor receptor (EGF-R; ErbB1) targeting molecules for wound healing or treatment of cancer as of September 2009 Purchase of the downloadable pdf report...